|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 13, 2018 ) Osteoporosis is a “silent epidemic” and as per the WHO declarations, it is a priority health issue. Osteoporosis is a disruption of bone architecture and decrease in bone mass, leading to a number of complications including increased chances of bone fractures and reduced bone strength. The most common sites of osteoporosis are the spine, hip and forearm, although it also affects other body parts.
Get Sample Copy Of This Report at http://www.orbisresearch.com/contacts/request-sample/2262428
The chronic nature of the disease, which requires ongoing treatment, relatively high annual cost of therapy (ACoT) of premium therapies, increasing prevalence and awareness about the disease among the patients over a period of time, and growing demand for mainly anabolic therapies, with only one anabolic therapy currently available in the market, have made osteoporosis treatment a highly lucrative market.
The osteoporosis therapeutic market has become very competitive due to the high number of new drug approvals, although the majority of them are incremental innovations of existing therapies. Competition is fierce, particularly among bisphosphonates and selective estrogen receptor modulators (SERMs), which are mostly used as first-line therapy and dominate the treatment market for osteoporosis patients.
Lack of effective and safe therapeutic options to treat osteoporosis was the major reason for development of currently marketed premium anabolic therapies. The competition among the premium therapies is expected to intensify during the forecast period due to expected launch of pipeline products. Additionally the expected launch of biosimilars will add fuel to the intense competition and make it tough for premium therapies to gain market share in the forecast period.
Patient compliance for osteoporosis therapies is a major unmet need, as the disease is asymptomatic until a fracture occurs and requires ongoing treatment. Drug delivery is crucial in the choice of medication.
Most medicines are administered orally, while others are administered intranasally or through injections. Medications with decreased dosing are often the preferred options. Therefore convenient and safe administration without significant compromise of therapy efficacy remains an unmet need.
Scope
- The current Asia-Pacific osteoporosis market contains novel products, including a humanized anti-sclerostin mAb, a synthetic peptide analog of human PTHrP, and a recombinant peptide and analogue of PTH.
- What are the competitive advantages of the novel drugs over current marketed drugs?
- Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy.
- Will the drugs under development fulfill the unmet needs of the osteoporosis market?
- The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies. There are over 136 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent in the pipeline?
- What is the potential for pipeline products to address unmet needs in the osteoporosis market?
- Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis patients?
- Analysis of clinical trials since 2006 identified that the failure rates of osteoporosis molecules were highest in Phase III, with the overall attrition rate for osteoporosis standing at 83%.
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Reasons to buy
- Understand the clinical context of osteoporosis by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and local and national registries.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
- Consider market opportunities and potential risks by examining trends in osteoporosis clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in osteoporosis by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia, Japan and South Korea.
- Discover trends in licensing and co-development deals concerning osteoporosis products and identify the major strategic consolidations that have shaped the commercial landscape.
Enquire before Buying at http://www.orbisresearch.com/contacts/enquiry-before-buying/2262428
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
